Spots Global Cancer Trial Database for A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Official Title: A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Study ID: NCT01525394

Conditions

Refractory Solid Tumors

Lymphomas

Interventions

Lenvatinib

Moxifloxacin 400 mg

Placebos (matched to 4 mg and 10 mg lenvatinib capsules).

Study Description

Brief Summary: This is a double-blind (vis-a-vis lenvatinib), randomized, placebo-controlled, three-treatment, three-way crossover study in healthy subjects. There are two phases in this study: Pre-Randomization and Randomization. The Pre-Randomization Phase consists of Screening and Baseline Period 1. The Randomization Phase consists of five periods: Treatment Period 1, Baseline Period 2, Treatment Period 2, Baseline Period 3, and Treatment Period 3. Completion of study termination procedures will be performed at Visit 11.

Detailed Description: